Vaccine-stimulated, adoptively transferred CD8+ T cells traffic indiscriminately and ubiquitously while mediating specific tumor destruction

Journal of Immunology

Volumn 173, Issue 12, 2004, Pages 7209-7216

  Palmer, Douglas C ^a   Balasubramaniam, Sanjeeve ^a   Hanada, Ken Ichi ^a   Wrzesinski, Claudia ^a   Yu, Zhiya ^a   Farid, Shahram ^a   Theoret, Marc R ^b   Hwang, Leroy N ^a   Klebanoff, Christopher A ^b   Gattinoni, Luca ^a   Goldstein, Allan L ^c   Yang, James C ^a   Restifo, Nicholas P ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 METHYLCHOLANTHRENE; CD8 ANTIGEN; GLYCOPROTEIN GP 100; RECOMBINANT INTERLEUKIN 2; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL MODEL; ARTICLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; GENE EXPRESSION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TRANSGENIC MOUSE; TUMOR GROWTH; TUMOR REGRESSION; VACCINATION;

EID: 10344234215     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.173.12.7209     Document Type: Article

References (42)

1. Ho, W. Y., J. N. Blattman, M. L. Dossett, C. Yee, and P. D. Greenberg. 2003. Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction. Cancer Cell 3:431.
2. 111indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy: augmentation with cyclophosphamide and correlation with response. Cancer 73:1731.
3. Mukai, S., J. Kjargaard, S. Shu, and G. E. Plautz. 1999. Infiltration of tumors by systemically transferred tumor-reactive T lymphocytes is required for antitumor efficacy. Cancer Res. 59:5245.
4. Karin, N., F. Szafer, D. Mitchell, D. P. Gold, and L. Steinman, 1993. Selective and nonselective stages in homing of T lymphocytes to the central nervous system during experimental allergic encephalomyelitis. J. Immunol. 150:4116.
5. Mora, J. R., M. R. Bono, N. Manjunath, W. Weninger, L. L. Cavanagh, M. Rosemblatt, and U. H. Von Andrian. 2003. Selective imprinting of gut-homing T cells by Peyer's patch dendritic cells. Nature 424:88.
6. Westermann, J., V. Blaschke, G. Zimmermann, U. Hirschfeld, and R. Pabst. 1992. Random entry of circulating lymphocyte subsets into peripheral lymph nodes and Peyer's patches: no evidence in vivo of a tissue-specific migration of B and T lymphocytes at the level of high endothelial venules. Eur. J. Immunol. 22:2219.
7. + T cells to the lung airways during respiratory virus infections. J. Immunol. 170:1423.
8. + T cells. Immunol. Rev. 186:221.
9. + T cells. J. Exp. Med. 198:569.
10. Dudley, M. E., J. R. Wunderlich, P. F. Robbins, J. C. Yang, P. Hwu, D. J. Schwartzentruber, S. L. Topalian, R. Sherry, N. P. Restifo, A. M. Hubicki, et al. 2002. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298:850.
11. Kwon, B. S., R. Halaban, S. Ponnazhagan, K. Kim, C. Chintamaneni, D. Bennett, and R. T. Pickard. 1995. Mouse silver mutation is caused by a single base insertion in the putative cytoplasmic domain of Pmel 17. Nucleic Acids Res. 23:154.
12. Tokunaga, K., K. Yoda, and S. Sakiyama. 1985. Structure of a processed gene of mouse cytoplasmic γ-actin transposed into a BAM5 sequence: insertion has created 13 base-pair direct repeats. Nucleic Acids Res. 13:3031.
13. Restifo, N. P., I. Bacik, K. R. Irvine, J. W. Yewdell, B. J. McCabe, R. W. Anderson, L. C. Eisenlohr, S. A. Rosenberg, and I. R. Bennink. 1995. Antigen processing in vivo and the elicitation of primary CTL responses. J. Immunol. 154:4414.
14. + T cells during an acute virus infection. Immunity 8:167.
15. Wong, P., and E. G. Pamer. 2003. CD8 T cell responses to infectious pathogens. Annu. Rev. Immunol. 21:29.
16. Bohm, W., S. Thoma, F. Leithauser, P. Moller, R. Schirmbeck, and J. Reimann. 1998. T cell-mediated, IFN-γ-facilitated rejection of murine B16 melanomas. J. Immunol. 161:897.
17. Kagi, D., F. Vignaux, B. Ledermann, K. Burki, V. Depraetere, S. Nagata, H. Hengartner, and P. Golstein. 1994. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science 265:528.
18. Lieberman, J. 2003. The ABCs of granule-mediated cytotoxicity: new weapons in the arsenal. Nat. Rev. Immunol. 3:361.
19. Rosenberg, S. A., J. C. Yang, P. F. Robbins, J. R. Wunderlich, P. Hwu, R. M. Sherry, D. J. Schwartzentruber, S. L. Topalian, N. P. Restifo, A. Filie, et al. 2003. Cell transfer therapy for cancer: lessons from sequential treatments of a patient with metastatic melanoma. J. Immunother. 26:385.
20. Luangsay, S., L. H. Kasper, N. Rachinel, L. A. Minns, F. J. Mennechet, A. Vandewalle, and D. Buzoni-Gatel. 2003. CCR5 mediates specific migration of Toxoplasma gondii-primed CD8 lymphocytes to inflammatory intestinal epithelial cells. Gastroenterology 125:491.
21. Jones, T. R., N. Shirasugi, A. B. Adams, T. C. Pearson, and C. P. Larsen. 2003. Intravital microscopy identifies selectins that regulate T cell traffic into allografts. J. Clin. Invest. 112:1714.
22. + T cells specific for a skin-tropic virus. J. Clin. Invest. 110:537.
23. Kershaw, M. H., G. Wang, J. A. Westwood, R. K. Pachynski, H. L. Tiffany, F. M. Marincola, E. Wang, H. A. Young, P. M. Murphy, and P. Hwu. 2002. Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. Hum. Gene Ther. 13:1971.
24. Peled, A., I. Petit, O. Kollet, M. Magid, T. Ponomaryov, T. Byk, A. Nagler, H. Ben-Hur, A. Many, L. Shultz, et al. 1999. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science 283:845.
25. Yu, P., Y. Lee, W. Liu, R. K. Chin, J. Wang, Y. Wang, A. Schietinger, M. Philip, H. Schreiber, and Y. X. Fu. 2004. Priming of naive T cells inside tumors leads to eradication of established tumors. Nat. Immunol. 5:141.
26. Marchand, M., N. van Baren, P. Weynants, V. Brichard, B. Dreno, M. H. Tessier, E. Rankin, G. Parmiani, F. Arienti, Y. Humblet, et al. 1999. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int. J. Cancer 80:219.
27. + T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl. Acad. Sci. USA 99:16168.
28. Vijh, S., I. M. Pilip, and E. G. Pamer. 1998. Effect of antigen-processing efficiency on in vivo T cell response magnitudes. J. Immunol. 160:3971.
29. Danna, E. A., P. Sinha, M. Gilbert, V. K. Clements, B. A. Pulaski, and S. Ostrand-Rosenberg. 2004. Surgical removal of primary tumor reverses tumor-induced immunosuppression despite the presence of metastatic disease. Cancer Res. 64:2205.
30. Speiser, D. E., R. Miranda, A. Zakarian, M. F. Bachmann, K. McKall-Faienza, B. Odermatt, D. Hanahan, R. M. Zinkernagel, and P. S. Ohashi. 1997. Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: implications for immunotherapy. J. Exp. Med. 186:645.
31. Dhodapkar, M. V., J. W. Young, P. B. Chapman, W. I. Cox, J. F. Fonteneau, S. Amigorena, A. N. Houghton, R. M. Steinman, and N. Bhardwaj. 2000. Paucity of functional T-cell memory to melanoma antigens in healthy donors and melanoma patients. Clin. Cancer Res. 6: 4831.
32. Khong, H. T., and N. P. Restifo. 2002. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat. Immunol. 3:999.
33. Romero, P., P. R. Dunbar, D. Valmori, M. Pittet, G. S. Ogg, D. Rimoldi, J. L. Chen, D. Lienard, J. C. Cerottini, and V. Cerundolo. 1998. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J. Exp. Med. 188:1641.
34. Lefrancois, L., A. Marzo, and K. Williams. 2003. Sustained response initiation is required for T cell clonal expansion but not for effector or memory development in vivo. J. Immunol. 171:2832.
35. Houghton, A. N., J. S. Gold, and N. E. Blachere. 2001. Immunity against cancer: lessons learned from melanoma. Curr. Opin. Immunol. 13:134.
36. + T cell differentiation: initial antigen encounter triggers a developmental program in naive cells. Nat. Immunol. 2:415.
37. + T lymphocyte responses. Nat. Immunol. 4:361.
38. + T cells during infection with respiratory syncytial virus are mediated by IFN-γ. Eur. J. Immunol. 32:2117.
39. + effector T cells reject tumors by direct antigen recognition but indirect action on host cells. J. Immunol. 170:4427.
40. Zhang, D., P. J. Beresford, A. H. Greenberg, and J. Lieberman. 2001. Granzymes A and B directly cleave lamins and disrupt the nuclear lamina during granule-mediated cytolysis. Proc. Natl. Acad. Sci. USA 98:5746.
41. Rosenberg, S. A., J. C. Yang, and N. P. Restifo. 2004. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10:909.
42. Morgan, R. A., M. E. Dudley, Y. Y. Yu, Z. Zheng, P. F. Robbins, M. R. Theoret, J. R. Wunderlich, M. S. Hughes, N. P. Restifo, and S. A. Rosenberg. 2003. High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens. J. Immunol. 171:3287.